Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Intracerebral Stem Cells (CTX0E03) in Subjects With Disability Following an Ischemic Stroke

X
Trial Profile

A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Intracerebral Stem Cells (CTX0E03) in Subjects With Disability Following an Ischemic Stroke

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ReN 001 (Primary)
  • Indications Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms PISCES III
  • Sponsors ReNeuron
  • Most Recent Events

    • 08 Jul 2021 Status changed from active, no longer recruiting to discontinued, due to strategic decision to progress stroke disability programme through regional partnerships.
    • 17 Jun 2020 Status changed from recruiting to active, no longer recruiting.
    • 17 Jun 2020 According to an ReNeuron media release, patient recruitment in this study with CTX in stroke disability, which has been on hold due to COVID-19 related restrictions, will remain suspended in the U.S. for the foreseeable future; clinical trial sites will be kept open and patients already treated will be followed up over time in line with the clinical trial protocol.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top